Site map

Home > Meetings > Past meetings

UK-CAB meetings are free and limited to 30 people. Meetings are interactive, with questions, discussions and time to network. Meetings are held in London.

Meetings

Past UK-CAB meetings

UK-CAB 35; 9 July 2010
Early Diagnosis and Primary Infection
Early Diagnosis and Primary Infection
CASCADE - Seroconverters Database
Vienna preview - a guide on what to look out for
Community meeting update from pharma
HIVA Feedback
UK-CAB 34; 18 June 2010
Community Training Day
What are observational studies
The UK Collaborative HIV Cohort Study
The UK HIV Drug Resistance Database
National Study of HIV in Pregnancy and Childhood
HPA Surveillance databases
New IT methods to protect data
How do we analyse observational databases
UK-CAB 33; 19 March 2010
African Treatment Issues and Late Diagnosis
Issues for African sub-groups
Pre-Meeting for Gilead
Community meeting update from Gilead, Q & A
CROI Feedback
UK-CAB 32; 22 January 2010
Advocacy training day
Confidence building workshop
Skill-building session
NHS structures in the UK
Getting other advocates involved
What next - active involvement
UK-CAB 31; 23 October 2009
Aging and HIV
UKCHIC Proposed Ageing Study
Ageing with HIV: Project Overview Will we ever get to be old and wise?
BHIVA Conference overview
Pre-meeting for Abbott
Community Meeting update from Abbott
Community Q & A with Abbott
HIV and Ageing interactive session
UK-CAB 30; 31 July 2009
BHIVA Routine Monitoring Guidelines
HIV Treatment Advocacy Overview
Definitions of Advocacy
Denver Principles
History of Advocacy Film highlights
Advocacy Training in Practice
Pre-Meeting for Bristol-Myers Squibb
Bristol-Myers Squibb Community Meeting, Q&A
Company meeting: BMS
IAS Conference Feedback
UK-CAB 29: 1 May 2009
Resistance Revisited
Introducing the HIV Vaccine Advisory
Board-Ken Legg, MRC and St Marys Hospital
Resistance Explored
Professor Deenan Pillay
Company meeting: GSK abacavir, pipeline drugs and merger
UK-CAB 28: 30 January 2009
"Late Presenters" BMS/Gilead patient education programme
Training and presentations: Immunology
Company meeting:Tibotec
 Etravirine overview including comment on drug interaction,
Darunavir European license extended to all treatment-experienced
Rilpivirine (TMC-278) Next generation first-line NNRTI
and pipeline HIV plus HCV and TB
UK-CAB 27: 24 October 2008
Transition from Paediatric Care to Adult Services.
Training and presentations: Mexico Feedback. BHIVA Education Scientific Committee Feedback. BHIVHA/CHIVHA Feedback. Update on the HCQ and PIVOT trials.
Transitional Care from Paediatric to Adult Services: A Clinical Care Perspective.
Young People and HIV: A Social Support Perspective
UK-CAB 26: 25 July 2008
TB and HIV - reporting adverse drug reactions - Theratechnologies
Training and presentations: TB and HIV - Yellow Card scheme for reporting adverse drug reactions - feedback from UNGASS, New York and Resistance Workshop, Sitges.
Company meeting: Theratechnologies
UK-CAB 25: 11 April 2008
Reading study results - D:A:D study - BHIVA treatment guidelines - GSK
Training and presentations: Interpreting risk and confidence in study results - D:A:D study: abacavir, ddI and risk of heart attack - conference feedback from CROI 2008.
Company meeting: GlaxoSmithKline - abacavir and data on risk of heart attack, drugs in development.
Community consultation: BHIVA draft treatment guidelines.
UK-CAB 24: 25 January 2008
BHIVA 2007 clinical audit - microbicides - PEPSE - PrEP - Pfizer
Training and presentations: BHIVA 2007 clinical audit: treatment of naïve patients - campaigning for microbicides - promoting PEPSE: role of the HIV treatment advocate - PrEP (pre-exposure prophylaxis).
Company meeting: Pfizer - the drug development process.
UK-CAB 23: 2 November 2007
Access to treatment for migrants and people facing deportation - Roche
Training and presentations: Access to treatment for migrants and people facing deportation: the clinician's perspective - HIV in removal centres - feedback from European AIDS Clinical Society Conference 2007, Madrid
Company meeting: Roche - nelfinavir recall, GEMINI study, Biojector.
UK-CAB 22: 13 July 2007
HIV testing and monitoring
Training and presentations: Rapid testing in practice - testing: the standard of care and some other useful tests - viral tropism - monitoring HIV infection and treatment in the 2nd decade of HAART - feedback from AIDS Impact Conference - Yellow Card scheme.
Company meeting: none.
UK-CAB 21: 20 April 2007
African treatment issues - Merck
Training and presentations: UK HIV drug resistance database - genetics and higher NNRTI levels in Africans - African treatment issues: response to treatment, side effects, treatment access and other issues - feedback from CROI 2007: new pipeline drugs.
Company meeting: Merck - raltegravir and integrase inhibitors.
UK-CAB 20: 26 January 2007
London HIV commissioning - renal toxicity - Gilead
Training and presentations: London HIV commissioning - renal toxicity studies.
Company meeting: Gilead - Atripla registration, renal studies and tenofovir, drugs in development.
UK-CAB 19: 24 November 2006
BHIVA standards project
Training and presentations: BHIVA standards project - feedback from International Congress on HIV and Drug Therapy 2006, Glasgow.
Company meeting: none.
UK-CAB 18: 1 September 2006
HIV related dementia
Training and presentations: HIV related brain impairment - feedback from World Haemophilia Congress 2006, Vancouver, AIDS 2006, Toronto and meetings on HIV transmission and criminalisation.
Company meeting: none.
UK-CAB 17: 26 May 2006
Cancer and HIV - Gilead
Training and presentations: Cancer and HIV - feedback from BHIVA, EATG and NAM seminar on new drugs.
Company meeting: Gilead - 'One a day' pill development, new integrase inhibitors.
UK-CAB 16: 24 February 2006
HIV related brain impairment - SMART study - Tibotec
Training and presentations: HIV related brain impairment - National Treatment Support Project - SMART study.
Company meeting: Tibotec - TMC-114 and TMC-125.
UK-CAB 15: 25 November 2005
Treatment access in eastern Europe - hepatitis C coinfection - Pfizer
Training and presentations:Treatment access in eastern Europe - hepatitis C coinfection - feedback from BHIVA conference, European AIDS Clinical Society Conference 2005, Dublin and International Workshop on Adverse Drug Reactions and Lipodystrophy 2005, Dublin - Global Fund.
Company meeting: Pfizer - CCR5 inhibitors.
UK-CAB 14: 19 August 2005
MRC Clinical Trials Unit - Roche
Training and presentations: Medical Research Council Clinical Trials Unit - feedback from 3rd IAS conference, Rio.
Company meeting: Roche - T20, Biojector and plans for its availability in the UK.
UK-CAB 13: 3 June 2005
Introduction to immunology - entry inhibitors.
Training and presentations: Introduction to immunology - entry inhibitors - feeback from BHIVA, CROI 2005 and South African PWA conference.
Company meeting: none.
UK-CAB 12: 28 January 2005
Children and HIV - UK treatment guidelines
Training and presentations: Approaches to paediatric HIV care - UK treatment guidelines.
Company meeting: none.
UK-CAB 11: 14 November 2004
Community participation in preventive HIV vaccine trials
Training and presentations:: Approaches to community participation in preventive HIV vaccine trials - feedback from International Congress on HIV and Drug Therapy 2004, Glasgow.
Company meeting: none.
UK-CAB 10: 13 August 2004
Introduction to statistics 3 - AIDS 2004 conference
Training and presentations: Introduction to statistics session 5-6 - feedback from AIDS 2004, Bangkok: mother-to-child transmission, harm reduction and IDUs, 3TC monotherapy, Kaletra monotherapy, pharmacology and drug interactions, treatment access.
Company meeting: none.
UK-CAB 9: 21 May 2004
Vaccines and microbicides - Tibotec
Training and presentations: Introduction to basic vaccine technology - topical microbicides - Internationl AIDS Vaccine Initiative (IAVI) - Community involvement in vaccine and microbicide research - thorny issues in HIV vaccine research - feedback from BHIVA conference.
Company meeting: Tibotec - TMC-120.
UK-CAB 8: 27 February 2004
Introduction to statistics 2 - BMS
Training and presentations: Introduction to statistics sessions 3-4 - hepatitis C coinfection: APRICOT study - feedback from CROI 2004: mother to child transmission, women, hepatitis C coinfection.
Company meeting: BMS - Atazanavir: update, access and pricing in UK.
UK-CAB 7: 21 November 2003
Introduction to statistics 1 - Gilead
Training and presentations: Introduction to statistics sessions 1-2.
Company meeting: Gilead - Tenofovir drug interactions.
UK-CAB 6: 8 August 2003
IAS conference feedback - GlaxoSmithKline
Training and presentations: New data from new data from 2nd IAS conference, Paris: Trizivir, emtricitabine, nuke-sparing combinations, atazanavir and boosted PI regimens T20, new formulations of nelfinavir and saquinavir, SIMBA study (reducing mother-to-baby transmission and breast-feeding) - feedback from lipodystrophy and resistance workshops.
Company meeting: GlaxoSmithKline - ACTG 5095 study, abacavir and tenofovir interaction, fosamprenavir, neuropathy, viral fitness.
UK-CAB 5: 2 May 2003
Access to treatment - TB and HIV - Roche
Training and presentations: Access to treatment in the UK: working with HIV-positive refugees and asylum seekers - TB and HIV.
Company meeting: Roche - T20.
UK-CAB 4: 31 January 2003
Women and HIV - HIV, coinfections and multiple conditions - Roche
Training and presentations: Women and HIV: why gender is a real issue - hepatitis C coinfection - living with multiple conditions - 48 weeks of interferon and ribavirin: was it worth it?
Company meeting: Roche - Hepatitis C products: trial results, side effects, pricing and access, future developments.
UK-CAB 3: 25 October 2002
HIV, pregnancy and maternal heath - Boehringer Ingelheim
Training and presentations: Of mothers, orphans and the HIV pandemic - Principles of care of the HIV-1 infected pregnant mother - Fertility treatment and spermashing.
Company meeting: Boehringer Ingelheim - Tipranavir: trials, resistance and clinical data, nevirapine use in pregnancy, drugs in development: hepatitis C protease inhibitor.
UK-CAB 2: 2 August 2002
Resistance - salvage therapy - BMS
Training and presentations: Basic mechanisms of resistance: how to avoid resistance, when to change treatment, how to interpret different resistance tests - approaches to salvage therapy: avoiding initial failure, mega-HAART including OPTIMA study, treatment interruptions, use of new drugs.
Company meeting: BMS - Atazanavir: overview, resistance, safety, side effects, lipids and expanded access programme, ddI interaction with tenofovir, d4T XR, BMS-561390 (DPC-083).
UK-CAB 1: 31 May 2002
UK-CABs - clinical trials - Gilead
Training and presentations: Clinical trials: structure, timelines, design, basic statistics and study power - informed consent and patient involvement in trial - role of advocates - UK, European and US CABs (Community Advisory Boards).
Company meeting: Gilead - tenofovir, adefovir for hepatitis B, cidofovir

Updated: 15 August 2008


This is a peer-led network. Information on this website is provided as a guide only.
Disclaimer | Privacy | Contact | About | RSS RSS